An Observational Study of MabThera/Rituxan (Rituximab) Plus Chemotherapy As First-Line Treatment in Patients With Diffuse Large B-Cell Lymphoma or Follicular Lymphoma
NCT ID: NCT01340443
Last Updated: 2017-11-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
314 participants
OBSERVATIONAL
2011-01-19
2016-07-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cohort
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Treatment with MabThera/Rituxan as per locally approved China package insert
* Documented patient with medical records
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hoffmann-La Roche
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Clinical Trials
Role: STUDY_DIRECTOR
Hoffmann-La Roche
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The Affiliated Hospital of Military Medical Sciences(The 307th Hospital of Chinese PLA)
Beijing, , China
the First Hospital of Jilin University
Changchun, , China
Xiangya Hospital of Centre-South University
Changsha, , China
Changzhou First People's Hospital
Changzhou, , China
Daqing Oilfield General Hospital
Daqing, , China
The First People's Hospital of Foshan
Foshan, , China
Fuzhou General Hospital, PLA Nanjing Military Area Command
Fuzhou, , China
Fujian Provincial Hospital
Fuzhou, , China
Nanfang Hospital, Southern Medical University
Guangzhou, , China
The affiliated Hospital of Guiyang Medical College
Guiyang, , China
The Second Affiliated Hospital of Zhejiang University College
Hangzhou, , China
Anhui Province Cancer Hospital
Hefei, , China
Affiliated Hospital of Inner Mongolia Medical College
Hohhot, , China
Shandong Cancer Hospital
Jinan, , China
The First Affilliated Hospital of Kunming Medical College
Kunming, , China
Lanzhou General Hospital, PLA Lanzhou Military Area Command
Lanzhou, , China
Jiangsu Cancer Hospital
Nanjing, , China
Hebei Medical University Fourth Hospital;(Tumor Hospital of Hebei Province)
Shijiazhuang, , China
Shanxi Province Cancer Hospital
Taiyuan, , China
Xiehe Hospital, Tongji Medical College Huazhong University of Science & Technology
Wuhan, , China
The Second Affiliated Hospital of The Fourth Military Medical University (Tangdu Hospital)
Xi'an, , China
Henan Cancer Hospital
Zhengzhou, , China
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, , China
Zhongshan General Hospital
Zhongshan, , China
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Wu JQ, Song YP, Su LP, Zhang MZ, Li W, Hu Y, Zhang XH, Gao YH, Niu ZX, Feng R, Wang W, Peng JW, Li XL, Ouyang XN, Wu CP, Zhang WJ, Zeng Y, Xiao Z, Liang YM, Zhuang YZ, Wang JS, Sun ZM, Bai H, Cui TJ, Feng JF. Three-year Follow-up on the Safety and Effectiveness of Rituximab Plus Chemotherapy as First-Line Treatment of Diffuse Large B-Cell Lymphoma and Follicular Lymphoma in Real-World Clinical Settings in China: A Prospective, Multicenter, Noninterventional Study. Chin Med J (Engl). 2018 Aug 5;131(15):1767-1775. doi: 10.4103/0366-6999.237401.
Wu J, Song Y, Su L, Xu L, Chen T, Zhao Z, Zhang M, Li W, Hu Y, Zhang X, Gao Y, Niu Z, Feng R, Wang W, Peng J, Li X, Ouyang X, Wu C, Zhang W, Zeng Y, Xiao Z, Liang Y, Zhuang Y, Wang J, Sun Z, Bai H, Cui T, Feng J. Rituximab plus chemotherapy as first-line treatment in Chinese patients with diffuse large B-cell lymphoma in routine practice: a prospective, multicentre, non-interventional study. BMC Cancer. 2016 Jul 26;16:537. doi: 10.1186/s12885-016-2523-7.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ML25435
Identifier Type: -
Identifier Source: org_study_id